Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Karyopharm granted orphan status for myelodysplastic syndrome treatment » 14:58
01/19/22
01/19
14:58
01/19/22
14:58
KPTI

Karyopharm

$7.69 /

+0.155 (+2.06%)

The FDA granted…

The FDA granted Karyopharm Therapeutics orphan status for extanexor, its treatment of myelodysplastic syndrome. Reference Link

ShowHide Related Items >><<
KPTI Karyopharm
$7.69 /

+0.155 (+2.06%)

KPTI Karyopharm
$7.69 /

+0.155 (+2.06%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$7.69 /

+0.155 (+2.06%)

KPTI Karyopharm
$7.69 /

+0.155 (+2.06%)

Over a week ago
Hot Stocks
Karyopharm names Sohanya Cheng as Chief Commercial Officer » 07:27
01/10/22
01/10
07:27
01/10/22
07:27
KPTI

Karyopharm

$7.07 /

-0.18 (-2.48%)

, ARWR

Arrowhead

$58.94 /

-1.92 (-3.15%)

Karyopharm Therapeutics…

Karyopharm Therapeutics (KPTI) announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the company's commercial strategy and operations, including the continued commercialization of XPOVIO. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations. Prior to joining Karyopharm, she served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals (ARWR).

ShowHide Related Items >><<
KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
11/16/21 Piper Sandler
Arrowhead selloff on hepatitis B data should be bought, says Piper Sandler
11/15/21 Piper Sandler
Piper Sandler bullish on Arrowhead following updated ARO-AAT, ARO-HSD data
10/29/21 B. Riley
B. Riley keeps $106 target on Arrowhead after ARO-C3 application
KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

ARWR Arrowhead
$58.94 /

-1.92 (-3.15%)

Hot Stocks
Karyopharm sees Q4 net product revenues of XPOVIO $29.7M » 07:17
01/10/22
01/10
07:17
01/10/22
07:17
KPTI

Karyopharm

$7.07 /

-0.18 (-2.48%)

Karyopharm Therapeutics…

Karyopharm Therapeutics announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the company's first-in-class, oral XPO1 inhibitor. Based on preliminary unaudited financial information, Karyopharm expects net product revenues of XPOVIO to be approximately $29.7M for the fourth quarter and approximately $98.3M for the full year 2021. Q4/FY21 revenue consensus is $30.88M/$114.03M, respectively. "For 2022, we are focused on making significant advances across our pipeline, beginning with top-line results from the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy following front-line chemotherapy in patients with advanced or metastatic endometrial cancer, which remain on track to be reported this quarter," said Richard Paulson, President and CEO of Karyopharm. "Building on the strong revenue growth in the second half of 2021, we will continue to prioritize driving sales and the adoption of XPOVIO in multiple myeloma. I am extremely pleased with the continued progress of our pipeline in key additional indications of multiple myeloma, myelodysplastic syndromes and myelofibrosis and our ability to further expand our impact on patients globally with our recent partnership with Menarini."

ShowHide Related Items >><<
KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

KPTI Karyopharm
$7.07 /

-0.18 (-2.48%)

Hot Stocks
Karyopharm, Menarini Group enter license agreement for NEXPOVIO » 07:31
12/21/21
12/21
07:31
12/21/21
07:31
KPTI

Karyopharm

$6.38 /

+0.205 (+3.32%)

Karyopharm Therapeutics…

Karyopharm Therapeutics and the Menarini Group announced their entry into an exclusive licensing agreement whereby Menarini will commercialize NEXPOVIO, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export compound, in Europe and other key global territories. Under the terms of the agreement, Menarini received exclusive rights to commercialize NEXPOVIO for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. In exchange, Karyopharm will receive an upfront payment of $75M in 2021 and is eligible to receive up to an additional $202.5M in future milestones, plus tiered double-digit royalties on net sales of NEXPOVIO in the licensed territories.

ShowHide Related Items >><<
KPTI Karyopharm
$6.38 /

+0.205 (+3.32%)

KPTI Karyopharm
$6.38 /

+0.205 (+3.32%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$6.38 /

+0.205 (+3.32%)

KPTI Karyopharm
$6.38 /

+0.205 (+3.32%)

Over a month ago
Hot Stocks
Karyopharm's partner Antengene receives marketing approval in China for XPOVIO » 08:39
12/17/21
12/17
08:39
12/17/21
08:39
KPTI

Karyopharm

$6.01 /

-0.24 (-3.84%)

Karyopharm Therapeutics…

Karyopharm Therapeutics announced that its partner, Antengene, has been granted conditional approval for marketing by the China National Medical Products Administration for XPOVIO, a first-in-class, oral selective inhibitor of nuclear export compound, in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received prior therapies and whose disease is refractory to at least a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Antengene has exclusive development and commercialization rights to selinexor in China and certain Asia Pacific countries. This conditional approval was based on the global Phase 2 STORM trial as well as results from Antengene's Phase 2 MARCH trial in China, which evaluated the efficacy and safety of selinexor plus dexamethasone in patients with relapsed/refractory multiple myeloma. The ongoing, randomized Phase 3 BENCH trial evaluating selinexor in combination with bortezomib and low-dose dexamethasone will serve as the confirmatory trial.

ShowHide Related Items >><<
KPTI Karyopharm
$6.01 /

-0.24 (-3.84%)

KPTI Karyopharm
$6.01 /

-0.24 (-3.84%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$6.01 /

-0.24 (-3.84%)

KPTI Karyopharm
$6.01 /

-0.24 (-3.84%)

Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 04:55
12/14/21
12/14
04:55
12/14/21
04:55
ABBV

AbbVie

$126.50 /

+1.035 (+0.82%)

, AGIO

Agios Pharmaceuticals

$31.66 /

+2.09 (+7.07%)

, CLLS

Cellectis

$8.41 /

-0.04 (-0.47%)

, EXAS

Exact Sciences

$78.10 /

-1.24 (-1.56%)

, EDIT

Editas Medicine

$29.28 /

+0.3 (+1.04%)

, BEAM

Beam Therapeutics

$76.94 /

+3.22 (+4.37%)

, AZN

AstraZeneca

$54.59 /

+0.58 (+1.07%)

, CYAD

Celyad

$4.43 /

+0.01 (+0.23%)

, GMAB

Genmab

$38.02 /

-0.005 (-0.01%)

, VIRX

Viracta Therapeutics

$3.82 /

-0.375 (-8.95%)

, TGTX

TG Therapeutics

$16.09 /

-0.48 (-2.90%)

, MBRX

Moleculin Biotech

$2.18 /

-0.135 (-5.84%)

, MBIO

Mustang Bio

$1.82 /

-0.245 (-11.86%)

, XNCR

Xencor

$33.87 /

+0.17 (+0.50%)

, SANA

Sana Biotechnology

$18.27 /

+0.665 (+3.78%)

, KPTI

Karyopharm

$6.03 /

+0.04 (+0.67%)

, GILD

Gilead

$69.90 /

+0.37 (+0.53%)

, DTIL

Precision BioSciences

$8.20 /

-0.39 (-4.54%)

, INCY

Incyte

$67.79 /

+2.51 (+3.84%)

, IMRA

Imara

$2.78 /

-0.04 (-1.42%)

, REGN

Regeneron

$660.15 /

-9.34 (-1.40%)

, MOR

MorphoSys

$9.19 /

-0.17 (-1.82%)

, NVS

Novartis

$80.83 /

+0.125 (+0.15%)

, BMY

Bristol-Myers

$59.05 /

+2.7 (+4.79%)

, FATE

Fate Therapeutics

$48.93 /

-0.24 (-0.49%)

, PFE

Pfizer

$55.23 /

+2.43 (+4.60%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GMAB Genmab
$38.02 /

-0.005 (-0.01%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

CYAD Celyad
$4.43 /

+0.01 (+0.23%)

CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

12/13/21 Cowen
Agios Pharmaceuticals named a best idea for 2022 at Cowen
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
CYAD Celyad
$4.43 /

+0.01 (+0.23%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-0.005 (-0.01%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$69.90 /

+0.37 (+0.53%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
INCY Incyte
$67.79 /

+2.51 (+3.84%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.78 /

-0.04 (-1.42%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$660.15 /

-9.34 (-1.40%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.83 /

+0.125 (+0.15%)

12/13/21 Credit Suisse
Novartis price target lowered to CHF 85 from CHF 90 at Credit Suisse
12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

12/13/21 Alliance Global Partners
Gamida Cell data at ASH meeting 'encouraging,' says Alliance Global Partners
12/13/21 Oppenheimer
Fate lymphoma update should erase concerns, says Oppenheimer
12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
PFE Pfizer
$55.23 /

+2.43 (+4.60%)

12/13/21
Fly Intel: Top five analyst upgrades
12/13/21 Citi
Arena 'highly attractive' for Pfizer, but FTC a concern, says Citi
12/13/21 Piper Sandler
Piper keeps $50 target on Ventyx after Pfizer buys Arena
12/13/21 UBS
Pfizer upgraded to Buy from Neutral at UBS
XNCR Xencor
$33.87 /

+0.17 (+0.50%)

VIRX Viracta Therapeutics
$3.82 /

-0.375 (-8.95%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

SANA Sana Biotechnology
$18.27 /

+0.665 (+3.78%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

MBRX Moleculin Biotech
$2.18 /

-0.135 (-5.84%)

MBIO Mustang Bio
$1.82 /

-0.245 (-11.86%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

DTIL Precision BioSciences
$8.20 /

-0.39 (-4.54%)

CLLS Cellectis
$8.41 /

-0.04 (-0.47%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

XNCR Xencor
$33.87 /

+0.17 (+0.50%)

TGTX TG Therapeutics
$16.09 /

-0.48 (-2.90%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

MOR MorphoSys
$9.19 /

-0.17 (-1.82%)

KPTI Karyopharm
$6.03 /

+0.04 (+0.67%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GMAB Genmab
$38.02 /

-0.005 (-0.01%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

FATE Fate Therapeutics
$48.93 /

-0.24 (-0.49%)

EXAS Exact Sciences
$78.10 /

-1.24 (-1.56%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

BEAM Beam Therapeutics
$76.94 /

+3.22 (+4.37%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

AGIO Agios Pharmaceuticals
$31.66 /

+2.09 (+7.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

REGN Regeneron
$660.15 /

-9.34 (-1.40%)

PFE Pfizer
$55.23 /

+2.43 (+4.60%)

NVS Novartis
$80.83 /

+0.125 (+0.15%)

INCY Incyte
$67.79 /

+2.51 (+3.84%)

IMRA Imara
$2.78 /

-0.04 (-1.42%)

GILD Gilead
$69.90 /

+0.37 (+0.53%)

EDIT Editas Medicine
$29.28 /

+0.3 (+1.04%)

BMY Bristol-Myers
$59.05 /

+2.7 (+4.79%)

AZN AstraZeneca
$54.59 /

+0.58 (+1.07%)

ABBV AbbVie
$126.50 /

+1.035 (+0.82%)

Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 04:55
12/13/21
12/13
04:55
12/13/21
04:55
ABBV

AbbVie

$125.46 /

+1.325 (+1.07%)

, AGIO

Agios Pharmaceuticals

$29.57 /

-0.99 (-3.24%)

, CLLS

Cellectis

$8.45 /

-0.26 (-2.99%)

, EXAS

Exact Sciences

$79.28 /

-1.82 (-2.24%)

, EDIT

Editas Medicine

$29.03 /

-1.48 (-4.85%)

, BEAM

Beam Therapeutics

$73.72 /

+0.22 (+0.30%)

, AZN

AstraZeneca

$54.01 /

-0.96 (-1.75%)

, CYAD

Celyad

$4.42 /

-0.59 (-11.78%)

, GMAB

Genmab

$38.02 /

-1.44 (-3.65%)

, VIRX

Viracta Therapeutics

$4.21 /

+0.01 (+0.24%)

, TGTX

TG Therapeutics

$16.57 /

-0.1 (-0.60%)

, MBRX

Moleculin Biotech

$2.33 /

+0.155 (+7.13%)

, MBIO

Mustang Bio

$2.07 /

-0.025 (-1.20%)

, XNCR

Xencor

$33.81 /

-0.36 (-1.05%)

, SANA

Sana Biotechnology

$17.61 /

-0.315 (-1.76%)

, KPTI

Karyopharm

$5.99 /

-0.47 (-7.28%)

, GILD

Gilead

$70.24 /

-0.06 (-0.09%)

, DTIL

Precision BioSciences

$8.59 /

-0.28 (-3.16%)

, INCY

Incyte

$65.39 /

-1.05 (-1.58%)

, IMRA

Imara

$2.84 /

-0.14 (-4.70%)

, REGN

Regeneron

$669.12 /

+3.38 (+0.51%)

, MOR

MorphoSys

$9.36 /

-0.44 (-4.49%)

, NVS

Novartis

$80.71 /

+0.255 (+0.32%)

, BMY

Bristol-Myers

$56.35 /

-1.21 (-2.10%)

, FATE

Fate Therapeutics

$49.17 /

-4.04 (-7.59%)

, PFE

Pfizer

$52.80 /

+0.705 (+1.35%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CYAD Celyad
$4.42 /

-0.59 (-11.78%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 H.C. Wainwright
Agios Pharmaceuticals price target raised to $93 from $88 at H.C. Wainwright
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
CYAD Celyad
$4.42 /

-0.59 (-11.78%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-1.44 (-3.65%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$70.24 /

-0.06 (-0.09%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
INCY Incyte
$65.39 /

-1.05 (-1.58%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.84 /

-0.14 (-4.70%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.71 /

+0.255 (+0.32%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
11/08/21 Citi
Fate Therapeutics upgraded to Buy from Neutral at Citi
11/05/21 Roth Capital
Fate Therapeutics price target lowered to $60 from $90 at Roth Capital
PFE Pfizer
$52.80 /

+0.705 (+1.35%)

12/10/21 Barclays
Pfizer price target raised to $54 from $44 at Barclays
12/09/21
Fly Intel: Top five analyst upgrades
12/09/21 Erste Group
Pfizer upgraded to Buy from Hold at Erste Group
12/08/21 Wells Fargo
Pfizer initiated with an Overweight at Wells Fargo
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

XNCR Xencor
$33.81 /

-0.36 (-1.05%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

Hot Stocks
Karyopharm presents updated Phase 2 Selinexor data » 16:18
12/12/21
12/12
16:18
12/12/21
16:18
KPTI

Karyopharm

$5.99 /

-0.47 (-7.28%)

Karyopharm Therapeutics …

Karyopharm Therapeutics announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with myelofibrosis previously treated with JAK inhibition. The results were based on the open label, prospective, investigator-initiated single center ESSENTIAL study in adult patients with primary or secondary MF with resistance or intolerance to JAK inhibitor therapy. Selinexor was administered orally at a dose of 80mg or 60mg once weekly to 12 patients. The primary endpoint of the study is to assess the efficacy of selinexor on SVR. Median duration of prior JAK inhibitor therapy was 22 months and 92% patients had MF refractory to ruxolitinib. As of the data cutoff, the median duration of treatment was 11 months. Of the ten patients who were on treatment for at least 24 weeks, four patients achieved SVR of greater than or equal to35% and six patients achieved SVR of greater than or equal to25%. Of the five patients who were transfusion dependent at screening, two achieved transfusion independence. Of the three patients with hemoglobin less than10g/dL at screening, improvement was observed in two patients. Reduction in marrow reticulin fibrosis from MF grade 3 to MF grade 1 was observed in a patient who had an assessment at week 72 demonstrating disease modification potential with longer treatment. While median overall survival was not yet reached, the two-year survival probability was assessed to be 91.7%. This compares favorably with a historical survival of 13-14 months in this population. The most common grade greater than or equal to 3 treatment emergent adverse events were anemia and fatigue. These were manageable with treatment interruption and dose reduction, except in one patient who discontinued treatment.

ShowHide Related Items >><<
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

Conference/Events
American Society of Hematology (ASH) to hold annual meeting » 14:45
12/12/21
12/12
14:45
12/12/21
14:45
ABBV

AbbVie

$125.46 /

+1.325 (+1.07%)

, AGIO

Agios Pharmaceuticals

$29.57 /

-0.99 (-3.24%)

, CLLS

Cellectis

$8.45 /

-0.26 (-2.99%)

, EXAS

Exact Sciences

$79.28 /

-1.82 (-2.24%)

, EDIT

Editas Medicine

$29.03 /

-1.48 (-4.85%)

, BEAM

Beam Therapeutics

$73.72 /

+0.22 (+0.30%)

, AZN

AstraZeneca

$54.01 /

-0.96 (-1.75%)

, CYAD

Celyad

$4.42 /

-0.59 (-11.78%)

, GMAB

Genmab

$38.02 /

-1.44 (-3.65%)

, VIRX

Viracta Therapeutics

$4.21 /

+0.01 (+0.24%)

, TGTX

TG Therapeutics

$16.57 /

-0.1 (-0.60%)

, MBRX

Moleculin Biotech

$2.33 /

+0.155 (+7.13%)

, MBIO

Mustang Bio

$2.07 /

-0.025 (-1.20%)

, XNCR

Xencor

$33.81 /

-0.36 (-1.05%)

, SANA

Sana Biotechnology

$17.61 /

-0.315 (-1.76%)

, KPTI

Karyopharm

$5.99 /

-0.47 (-7.28%)

, GILD

Gilead

$70.24 /

-0.06 (-0.09%)

, DTIL

Precision BioSciences

$8.59 /

-0.28 (-3.16%)

, INCY

Incyte

$65.39 /

-1.05 (-1.58%)

, IMRA

Imara

$2.84 /

-0.14 (-4.70%)

, REGN

Regeneron

$669.12 /

+3.38 (+0.51%)

, MOR

MorphoSys

$9.36 /

-0.44 (-4.49%)

, NVS

Novartis

$80.71 /

+0.255 (+0.32%)

, BMY

Bristol-Myers

$56.35 /

-1.21 (-2.10%)

, FATE

Fate Therapeutics

$49.17 /

-4.04 (-7.59%)

, PFE

Pfizer

$52.80 /

+0.705 (+1.35%)

63rd Annual Meeting of…

63rd Annual Meeting of ASH to be held in Atlanta, GA on December 11-14.Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CYAD Celyad
$4.42 /

-0.59 (-11.78%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
12/03/21 BofA
Agios Pharmaceuticals initiated with a Buy at BofA
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 H.C. Wainwright
Agios Pharmaceuticals price target raised to $93 from $88 at H.C. Wainwright
CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

11/30/21 JMP Securities
Cellectis initiated with an Outperform at JMP Securities
11/08/21 William Blair
Cellectis downgraded to Market Perform at William Blair on slow execution
11/08/21 William Blair
Cellectis downgraded to Market Perform from Outperform at William Blair
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

11/04/21 Raymond James
ASH abstracts justify Crispr Therapeutics concerns, says Raymond James
10/19/21 SVB Leerink
Editas Medicine initiated with a Market Perform at SVB Leerink
09/30/21 Stifel
Editas Medicine price target lowered to $46 from $65 at Stifel
09/29/21 Stifel
Efficacy the bigger question than safety for Editas' EDIT-101, says Stifel
BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
09/23/21 Stifel
Beam Therapeutics assumed at Buy from Hold at Stifel
09/10/21 BofA
Beam Therapeutics initiated with a Buy at BofA
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

12/07/21 Jefferies
AstraZeneca downgraded to Hold from Buy at Jefferies
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
CYAD Celyad
$4.42 /

-0.59 (-11.78%)

12/10/21 H.C. Wainwright
Celyad price target lowered to $13 from $15 at H.C. Wainwright
08/06/21 H.C. Wainwright
Celyad price target lowered to $15 from $17 at H.C. Wainwright
03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
GMAB Genmab
$38.02 /

-1.44 (-3.65%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 Berenberg
Genmab initiated with a Sell at Berenberg
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

05/03/21 H.C. Wainwright
Viracta Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 SVB Leerink
SVB Leerink bullish on Viracta Therapeutics, initiates with an Outperform
04/26/21 SVB Leerink
Viracta Therapeutics initiated with an Outperform at SVB Leerink
03/25/21
Fly Intel: Top five analyst initiations
TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

12/01/21 B. Riley
TG Therapeutics selloff yesterday may be unwarranted, says B. Riley
12/01/21 Evercore ISI
TG Therapeutics price target lowered to $36 from $55 at Evercore ISI
12/01/21 Cantor Fitzgerald
TG Therapeutics price target lowered to $54 from $70 at Cantor Fitzgerald
12/01/21 H.C. Wainwright
TG Therapeutics price target lowered to $75 from $84 at H.C. Wainwright
MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
02/01/21 Roth Capital
Moleculin Biotech price target adjusted to $29 after stock split at Roth Capital
MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

11/09/21 Piper Sandler
Xencor price target lowered to $71 from $75 at Piper Sandler
10/14/21 BTIG
Xencor assumed with a Buy at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
09/28/21 Guggenheim
Xencor price target lowered to $50 from $57 at Guggenheim
SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$70.24 /

-0.06 (-0.09%)

12/08/21 Wells Fargo
Gilead initiated with an Equal Weight at Wells Fargo
12/07/21 Piper Sandler
Gilead's lenacapavir opportunity remains intact, says Piper Sandler
12/06/21 Goldman Sachs
Gilead initiated with a Neutral at Goldman Sachs
11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

04/13/21
Precision BioSciences management to meet virtually with Truist
04/06/21 Stifel
Stifel sees Precision BioSciences' CEO transition as 'disconcerting'
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 JonesTrading
Precision BioSciences initiated with a Buy at JonesTrading
INCY Incyte
$65.39 /

-1.05 (-1.58%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
IMRA Imara
$2.84 /

-0.14 (-4.70%)

11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
08/11/21 Morgan Stanley
Imara downgraded to Equal Weight from Overweight at Morgan Stanley
03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

12/08/21 Wells Fargo
Regeneron initiated with an Overweight at Wells Fargo
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Cowen
Regeneron assumed with a Market Perform at Cowen
12/06/21 Goldman Sachs
Regeneron initiated with a Buy at Goldman Sachs
MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
NVS Novartis
$80.71 /

+0.255 (+0.32%)

12/06/21 Exane BNP Paribas
Novartis downgraded to Neutral from Outperform at Exane BNP Paribas
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Bryan Garnier
Novartis downgraded to Neutral on pipeline concerns at Bryan Garnier
12/03/21 Bryan Garnier
Novartis downgraded to Neutral from Buy at Bryan Garnier
BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

12/08/21 Wells Fargo
Bristol-Myers initiated with an Equal Weight at Wells Fargo
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

12/07/21 Cowen
Fate Therapeutics initiated with an Outperform at Cowen
11/08/21 Citi
Fate Therapeutics upgraded to Buy at Citi ahead of SITC and ASH presentations
11/08/21 Citi
Fate Therapeutics upgraded to Buy from Neutral at Citi
11/05/21 Roth Capital
Fate Therapeutics price target lowered to $60 from $90 at Roth Capital
PFE Pfizer
$52.80 /

+0.705 (+1.35%)

12/10/21 Barclays
Pfizer price target raised to $54 from $44 at Barclays
12/09/21
Fly Intel: Top five analyst upgrades
12/09/21 Erste Group
Pfizer upgraded to Buy from Hold at Erste Group
12/08/21 Wells Fargo
Pfizer initiated with an Overweight at Wells Fargo
XNCR Xencor
$33.81 /

-0.36 (-1.05%)

VIRX Viracta Therapeutics
$4.21 /

+0.01 (+0.24%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

SANA Sana Biotechnology
$17.61 /

-0.315 (-1.76%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

MBRX Moleculin Biotech
$2.33 /

+0.155 (+7.13%)

MBIO Mustang Bio
$2.07 /

-0.025 (-1.20%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

DTIL Precision BioSciences
$8.59 /

-0.28 (-3.16%)

CLLS Cellectis
$8.45 /

-0.26 (-2.99%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

  • 14
    Jul
  • 03
    Feb
  • 04
    Feb
  • 21
    Jan
  • 06
    Jan
  • 16
    Dec
  • 15
    Dec
REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

XNCR Xencor
$33.81 /

-0.36 (-1.05%)

TGTX TG Therapeutics
$16.57 /

-0.1 (-0.60%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

MOR MorphoSys
$9.36 /

-0.44 (-4.49%)

KPTI Karyopharm
$5.99 /

-0.47 (-7.28%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GMAB Genmab
$38.02 /

-1.44 (-3.65%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

FATE Fate Therapeutics
$49.17 /

-4.04 (-7.59%)

EXAS Exact Sciences
$79.28 /

-1.82 (-2.24%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

BEAM Beam Therapeutics
$73.72 /

+0.22 (+0.30%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

AGIO Agios Pharmaceuticals
$29.57 /

-0.99 (-3.24%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

REGN Regeneron
$669.12 /

+3.38 (+0.51%)

PFE Pfizer
$52.80 /

+0.705 (+1.35%)

NVS Novartis
$80.71 /

+0.255 (+0.32%)

INCY Incyte
$65.39 /

-1.05 (-1.58%)

IMRA Imara
$2.84 /

-0.14 (-4.70%)

GILD Gilead
$70.24 /

-0.06 (-0.09%)

EDIT Editas Medicine
$29.03 /

-1.48 (-4.85%)

BMY Bristol-Myers
$56.35 /

-1.21 (-2.10%)

AZN AstraZeneca
$54.01 /

-0.96 (-1.75%)

ABBV AbbVie
$125.46 /

+1.325 (+1.07%)

Conference/Events
Karyopharm to host virtual investor day » 09:25
12/08/21
12/08
09:25
12/08/21
09:25
KPTI

Karyopharm

$7.25 /

+0.52 (+7.73%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 8 at 10 am. Webcast Link

ShowHide Related Items >><<
KPTI Karyopharm
$7.25 /

+0.52 (+7.73%)

KPTI Karyopharm
$7.25 /

+0.52 (+7.73%)

11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
08/06/21 SVB Leerink
Karyopharm downgraded to Market Perform from Outperform at SVB Leerink
KPTI Karyopharm
$7.25 /

+0.52 (+7.73%)

KPTI Karyopharm
$7.25 /

+0.52 (+7.73%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.